

#### DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human CD30/TNFRSF8 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse CD30, recombinant human (rh) CD27, and rhCD40 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 81337
<b>Purification</b>	Protein A or G purified from ascites
<b>Immunogen</b>	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant human CD30/TNFRSF8 Phe19-Lys379 Accession # P28908
<b>Conjugate</b>	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
<b>Formulation</b>	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

#### APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	0.25-1 µg/10 <sup>6</sup> cells	Jurkat human acute T cell leukemia cell line

#### PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> ● 12 months from date of receipt, 2 to 8 °C as supplied.

#### BACKGROUND

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C-terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

#### References:

- Kennedy, M.K. *et al.* (2006) *Immunology* **118**:143.
- Tarkowski, M. (2003) *Curr. Opin. Hematol.* **10**:267.
- Durkop, H. *et al.* (1992) *Cell* **68**:421.
- Hamann, D. *et al.* (1996) *J. Immunol.* **156**:1387.
- Shanebeck, S.D. *et al.* (1995) *Eur. J. Immunol.* **25**:2147.
- Gruss, H.-J. *et al.* (1994) *Blood* **83**:2045.
- Ofizoglu E. *et al.* (2009) *Adv. Exp. Med. Biol.* **647**:174.
- Del Prete, G. *et al.* (1995) *J. Exp. Med.* **182**:1655.
- Harlin, H. *et al.* (2002) *J. Immunol.* **169**:2451.
- Amakawa, R. *et al.* (1996) *Cell* **84**:551.
- Chiarle, R. *et al.* (1999) *J. Immunol.* **163**:194.
- Vinante, F. *et al.* (2002) *Blood* **99**:52.
- Hansen, H.P. *et al.* (1995) *Int. J. Cancer* **63**:750.
- Hansen, H.P. *et al.* (2000) *J. Immunol.* **165**:6703.
- Hargreaves, P.G. and A. Al-Shamkhani (2002) *Eur. J. Immunol.* **32**:163.

**PRODUCT SPECIFIC NOTICES**

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.